These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37773882)

  • 21. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis.
    Moustafa B; Oparowski D; Testai S; Guman I; Trifan G
    J Stroke Cerebrovasc Dis; 2024 Apr; 33(4):107633. PubMed ID: 38336118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.
    Nagendra L; Mahajan K; Gupta G; Dutta D
    Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease.
    Delialis D; Dimopoulou MA; Papaioannou M; Kotsira G; Maneta E; Mavraganis G; Loutos C; Georgiopoulos G; Stamatelopoulos K
    Curr Pharm Des; 2023; 29(23):1802-1824. PubMed ID: 37055909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
    Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
    Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
    Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
    World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
    O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
    Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
    Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J
    BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 32. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
    Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
    Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCSK9 inhibitors in clinical practice: Novel directions and new experiences.
    Rallidis LS; Skoumas I; Liberopoulos EN; Vlachopoulos C; Kiouri E; Koutagiar I; Anastasiou G; Kosmas N; Elisaf MS; Tousoulis D; Iliodromitis E
    Hellenic J Cardiol; 2020; 61(4):241-245. PubMed ID: 31783124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
    Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
    Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease.
    Blumenthal DM; Maddox TM; Aragam K; Sacks CA; Virani SS; Wasfy JH
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007237. PubMed ID: 34404223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome.
    Sarak B; Savu A; Kaul P; McAlister FA; Welsh RC; Yan AT; Goodman SG
    Circ Cardiovasc Qual Outcomes; 2021 Apr; 14(4):e006646. PubMed ID: 33813856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
    Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
    J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.